Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis

C. H. Banov, T. R. Woehler, C. F. LaForce, D. S. Pearlman, M. N. Blumenthal, W. F. Morgan, H. Frazer, D. L. Southern, B. Gold, E. Field, K. Kral, P. R. Rogenes

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

The efficacy of intranasal fluticasone propionate 200 μg once daily or 100 μg twice daily in treating perennial allergic rhinitis was evaluated in a randomized, double-blind, placebo-controlled study of 24 weeks' duration in 365 patients. Clinician-rated and patient-rated total nasal symptom severity scores were improved within 1 week of treatment with either regimen of fluticasone propionate and improvement was maintained over the 24-week treatment period. Clinician-rated overall evaluation indicated a significantly better response in the two fluticasone propionate groups compared with the placebo group. All efficacy evaluations indicated no difference in response between the fluticasone propionate 200 μg once-daily and 100 μg twice-daily groups. Patients in both fluticasone propionate groups had significantly less nasal obstruction upon awakening than the placebo group at all assessment periods. Fewer patients in either fluticasone propionate group used antihistamine rescue medication compared with the placebo group. The percentage of patients with nasal eosinophils and basophils at the end of the 24-week treatment period was significantly lower in both fluticasone propionate groups compared with the placebo group. Safety evaluations indicated that intranasal fluticasone propionate was as safe as placebo when given as 200 μg once daily or 100 μg twice daily. The incidence of drug-related adverse events was similar among the fluticasone propionate and placebo groups except for the incidence of epistaxis and blood in nasal mucus which was somewhat higher in the fluticasone propionate twice- daily group. There were no changes in the ophthalmic examinations to suggest corticosteroid-induced posterior subcapsular cataract formation. Fluticasone propionate did not appear to affect the hypothalamic-pituitary-adrenal axis as determined by morning plasma cortisol concentrations and response to cosyntropin stimulation. Long-term administration of intranasal fluticasone propionate 200 μg once daily is an effective and well-tolerated treatment for perennial allergic rhinitis.

Original languageEnglish (US)
Pages (from-to)240-246
Number of pages7
JournalAnnals of Allergy
Volume73
Issue number3
StatePublished - Sep 28 1994

Fingerprint Dive into the research topics of 'Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis'. Together they form a unique fingerprint.

Cite this